John J. Reddington
Directeur/Membre du Conseil chez 3Brain AG
Postes actifs de John J. Reddington
Sociétés | Poste | Début | Fin |
---|---|---|---|
3Brain AG
3Brain AG Information Technology ServicesTechnology Services 3Brain AG is a Swiss company that specializes in improving in vitro cell-based screening outputs to find new treatments for brain diseases. The private company is located in Wädenswil, Switzerland. The company is the world's first company to connect cells with sophisticated biosignal processing microchips in vitro. The CEO of the company is Mauro Gandolfo. | Directeur/Membre du Conseil | - | - |
Grid News Bureau LLC | Directeur/Membre du Conseil | - | - |
Historique de carrière de John J. Reddington
Anciens postes connus de John J. Reddington
Sociétés | Poste | Début | Fin |
---|---|---|---|
Morris Animal Foundation
Morris Animal Foundation Miscellaneous Commercial ServicesCommercial Services Morris Animal Foundation operates as an animal health charity. It helps support the advancement of veterinary medicine and funds veterinary research for companion animals, horses, and wildlife. The company was founded by Mark Morris Sr. in 1948 and is headquartered in Denver, CO. | Directeur Général | 17/05/2016 | 01/02/2018 |
President | 17/05/2016 | 01/02/2018 | |
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Directeur des opérations | 01/05/2003 | 01/11/2006 |
Formation de John J. Reddington
Washington State University | Doctorate Degree |
The University of Texas at Austin | Graduate Degree |
Rice University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 7 |
Suisse | 2 |
Opérationnelle
Director/Board Member | 2 |
Chief Operating Officer | 1 |
Doctorate Degree | 1 |
Sectorielle
Consumer Services | 4 |
Health Technology | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 4 |
---|---|
Valentis, Inc.
Valentis, Inc. Pharmaceuticals: MajorHealth Technology Valentis lead drug candidate, Deltavasc, may treat peripheral arterial and ischemic heart disease with a gene that spurs new blood vessels to form (a process known as angiogenesis). In early stages of development are DNA vaccines for HIV, hepatitis C, and other viral infections. Another drug candidate, eNOS, could prevent tissue rejection in transplant recipients. The company licenses its technology -- include the GeneSwitch platform, which can turn off or on gene therapies -- to other drugmakers. These licensees include Genzyme, Pfizer, and GlaxoSmithKline. | Health Technology |
Morris Animal Foundation
Morris Animal Foundation Miscellaneous Commercial ServicesCommercial Services Morris Animal Foundation operates as an animal health charity. It helps support the advancement of veterinary medicine and funds veterinary research for companion animals, horses, and wildlife. The company was founded by Mark Morris Sr. in 1948 and is headquartered in Denver, CO. | Commercial Services |
3Brain AG
3Brain AG Information Technology ServicesTechnology Services 3Brain AG is a Swiss company that specializes in improving in vitro cell-based screening outputs to find new treatments for brain diseases. The private company is located in Wädenswil, Switzerland. The company is the world's first company to connect cells with sophisticated biosignal processing microchips in vitro. The CEO of the company is Mauro Gandolfo. | Technology Services |
Grid News Bureau LLC |
- Bourse
- Insiders
- John J. Reddington
- Expérience